Erratum: Effects of Cross-Sex Hormone Treatment on Transgender Women and Men (Obstet Gynecol (2015) 125 (605-610) DOI: 10.1097/AOG.0000000000000692);Effects of cross-sex hormone treatment on transgender women and men

Obstetrics and Gynecology

Volumn 125, Issue 3, 2015, Pages 605-610

  Deutsch, Madeline B ^a,b   Bhakri, Vipra ^a,b   Kubicek, Katrina ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL VALERATE; ESTROGEN; TESTOSTERONE; TESTOSTERONE CIPIONATE; ESTRADIOL; LIPID;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CROSS SEX HORMONE TREATMENT; FEASIBILITY STUDY; FEMALE; HEALTH CENTER; HORMONAL THERAPY; HORMONE DETERMINATION; HUMAN; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRANSGENDER; UNITED STATES; BLOOD; BLOOD PRESSURE; DRUG EFFECTS; MIDDLE AGED; PROSPECTIVE STUDY; SEX REASSIGNMENT; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; BLOOD PRESSURE; BODY MASS INDEX; ESTRADIOL; FEASIBILITY STUDIES; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEX REASSIGNMENT PROCEDURES; TESTOSTERONE; TRANSGENDER PERSONS; YOUNG ADULT;

EID: 84923620234     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000005610     Document Type: Erratum

References (22)

1. Dahl M, Feldman JL, Goldberg JM, Jaberi A. Physical aspects of transgender endocrine therapy. Int J Transgend 2006;9(3-4): 111-34.
2. Ott J, Aust S, Promberger R, Huber JC, Kaufmann U. Cross-sex hormone therapy alters the serum lipid profile: a retrospective cohort study in 169 transsexuals. J Sex Med 2011;8:2361-9.
3. Wierckx K, Elaut E, Declercq E, Heylens G, De Cuypere G, Taes Y, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol 2013;169:471-8.
4. Elamin MB, Garcia MZ, Murad MH, Erwin PJ, Montori VM. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-Analyses. Clin Endocrinol (Oxf) 2010;72:1-10.
5. Gooren LJ. Care of transsexual persons. N Engl J Med 2011; 364:1251-7.
6. Hembree WC, Cohen-Kettenis P, Delemarre-van De Waal HA, Gooren LJ, Meyer WJ 3rd, Spack NP, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009;94:3132-54.
7. The health of lesbian, gay, bisexual, and transgender people: building a foundation for better understanding. Institute of Medicine; 2011. Available at: http://www.iom.edu/Reports/2011/The-Health-of-Lesbian-Gay-Bisexual-And-Transgender-People.aspx. Retrieved November 1, 2014.
8. Deutsch MB. Use of the informed consent model in the provision of cross-sex hormone therapy: a survey of the practices of selected clinics. Int J Transgend 2012;13:140-6.
9. Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW. Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta-estradiol. Obstet Gynecol 1997;89:340-5.
10. Ahokas A, Kaukoranta J, Wahlbeck K, Aito M. Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17beta-estradiol: a preliminary study. J Clin Psychiatry 2001;62:332-6.
11. Al-Futaisi AM, Al-Zakwani IS, Almahrezi AM, Morris D. Subcutaneous administration of testosterone-A pilot study report. Saudi Med J 2006;27:1843-6.
12. Olson J, Schrager SM, Clark LF, Dunlap SL, Belzer M. Subcutaneous testosterone: an effective delivery mechanism for masculinizing young transgender men. LGBT Health 2014;1: 165-7.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
14. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee ( JNC 8). JAMA 2014;311:507-20.
15. Third report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Heart, Lung and Blood Institute; 2012. Available at: http://www.nhlbi.nih.gov/health-pro/guidelines/current/cholesterol-guidelines/. RetrievedNovember 1, 2014.
16. Stone NJ, Robinson JG, Lichtenstein AH, Goff DC Jr, Lloyd-Jones DM, Smith SC, et al. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Intern Med 2014;160:339-43.
17. Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008;93:19-25.
18. Baba T, Endo T, Honnma H, Kitajima Y, Hayashi T, Ikeda H, et al. Association between polycystic ovary syndrome and female-to-male transsexuality. Hum Reprod 2007;22:1011-6.
19. Perrone AM, Cerpolini S, Maria Salfi NC, Ceccarelli C, De Giorgi LB, Formelli G, et al. Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals. J Sex Med 2009;6:3193-200.
20. Bauer GR, Travers R, Scanlon K, Coleman TA. High heterogeneity of HIV-related sexual risk among transgender people in Ontario, Canada: a province-wide respondent-driven sampling survey. BMC Public Health 2012;12:292.
21. Kuyper L, Wijsen C. Gender identities and gender dysphoria in the Netherlands. Arch Sex Behav 2014;43:377-85.
22. De Cuypere G, Van Hemelrijck M, Michel A, Carael B, Heylens G, Rubens R, et al. Prevalence and demography of transsexualism in Belgium. Eur Psychiatry 2007;22:137-41.